Novozymes and Chr. Hansen to combine and create a leading global biosolutions partner

On December 12, 2022, Novozymes and Chr. Hansen announced that they have entered into an agreement to create a leading global biosolutions partner through a statutory merger of the two companies.

On March 30, 2023, Novozymes’ and Chr. Hansen’s shareholders approved the combination to create a leading global biosolutions partner. The completion of the proposed merger is subject to customary merger control and other regulatory approvals from relevant authorities.

Please see below for documents and other relevant information regarding the proposed merger.




Investor relations 

Anders Mohr Christensen

Head of Investor Relations & Strategy

+45 2515 2364

Press relations

Sanne Seyer-Hansen

Head of Corporate Communications

+45 6038 6207 

Restricted access

Access to this Website and the information contained herein is limited to persons resident:

  • in Denmark; OR
  • in the United States who are "qualified institutional buyers" as defined in Rule 144A under the U.S. Securities Act of 1933, as amended ("Securities Act") pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and who have executed an investor letter; OR
  • outside Denmark, the United States, Australia, Canada, South Africa, Japan and any jurisdiction in which it would be unlawful to access any prospectus, exemption document or other offer materials published by Chr. Hansen in connection with the proposed transaction.